Mounjaro 8-Week Weight Loss: A Realistic Week-by-Week Picture

Step 1: Weeks 1–4, the body's adjustment period

The first four weeks on Mounjaro are about tolerance, not transformation. Treatment opens at 2.5mg, a dose chosen specifically because it gives your digestive system time to adapt to tirzepatide's dual GIP and GLP-1 receptor activity before the therapeutic work really begins. Nausea, a feeling of fullness after small meals, and occasional loose stools are common in this window; they settle for most people within the first couple of weeks.

Weight loss during weeks one to four tends to be small, often two to four kilograms, sometimes less, occasionally more depending on how much someone has also adjusted their eating. Some of that early drop is water and glycogen rather than fat. That doesn't make it meaningless, but it does mean week-four results are not a reliable signal of how the medicine will perform at month six.

The NHS medicines page for tirzepatide explains the starting schedule and common early side effects in plain language, useful reading before your first pen arrives.

Step 2: Weeks 5–8, appetite suppression becomes clearer

By week five, many people notice that appetite suppression is more consistent. The feeling of being full after a smaller portion, and less pull toward high-calorie foods between meals, tends to become more noticeable as tirzepatide reaches steady state in the bloodstream. You can read more about what patients often experience at this point on our week-five plateau page, which addresses the very common situation where the scales stall briefly mid-dose.

A prescriber may move someone from 2.5mg to 5mg around week five if tolerance has been good, though timing is always an individual clinical decision. The dose increase often brings a fresh wave of appetite reduction and, for some, a return of mild GI symptoms for a few days. Weight loss in weeks five to eight is usually more consistent than the opening month, though it still varies. People often see somewhere between one and two kilograms per week at this stage, less in some weeks, occasionally more.

The broader pattern of weekly weight loss on Mounjaro shows clearly that the trajectory is not linear, some weeks produce more movement than others.

Step 3: Reading the eight-week number in context

At the end of eight weeks, a reasonable range for weight lost on Mounjaro (accounting for both the starter dose period and an early 5mg period) is roughly four to eight kilograms, though individual results sit outside that range in both directions. The SURMOUNT-1 trial, published in the New England Journal of Medicine, found that meaningful, sustained loss continued well beyond two months, with the strongest results at 72 weeks for participants on the highest doses.

It's worth keeping a broader frame in mind: eight weeks is early. The medicine is not yet at therapeutic maintenance doses for most people, and the lifestyle changes that amplify the medicine's effect (protein-adequate meals, strength exercise, adequate sleep) compound over months. If week eight feels slow, that's not unusual and not a signal to stop.

One thing our prescribers hear regularly: people who order at the end of the month or around bank holidays worry about gaps in supply. Ordering before the 12pm Monday–Friday cut-off on a working day keeps the chain unbroken, once approved, treatment ships same day and arrives with DPD the next working day. A gap in treatment can disrupt tolerance and appetite suppression, so it's worth planning ahead around paydays and holidays.

For a fuller look at how results develop across the whole treatment timeline, the complete week-by-week breakdown covers what the evidence shows at each stage. And if you're weighing up whether Mounjaro is the right option, our overview of how Mounjaro works for weight loss covers eligibility, the evidence base and what to expect from treatment as a whole.

What to do if eight weeks hasn't produced the results you hoped for

A slow start does not mean treatment isn't working. There are a few practical questions worth asking at the eight-week mark. Has diet changed alongside the medicine, or has appetite suppression been used as a licence to eat differently without reducing overall intake? Is sleep adequate? Is there a medical reason (thyroid, medication interactions) that hasn't been reviewed?

The right place to bring these questions is your prescriber, not a forum. At nume, every repeat order goes back in front of a clinician for review, the same GPhC-registered prescriber model that handled the initial consultation, not an automated system. If something isn't working as expected, that's exactly the kind of thing a clinical review exists to address.

For anyone who is still on the 2.5mg starting dose at week eight and wondering whether the treatment is doing anything, it's also worth reading about what no weight loss in the second week usually means, the clinical picture there often applies just as well at eight weeks.

Tirzepatide is explored in detail (mechanism, eligibility and the full evidence base) on our tirzepatide information page. The NICE appraisal of tirzepatide (NICE TA1026) also sets out what the evidence shows and which patients NICE considers suitable. If you're ready to talk to a prescriber about your own situation, start your free consultation here.